EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Rodriguez-Martinez, CE
  • Ordonez, J
  • Carbonell-Estrany, X
  • Fullarton, J
  • Keary, I
  • Rodgers-Gray, B
  • D'Apremont, I
  • Espinosa, SM
  • Ribeiro, PA
  • Stein, R
  • Vain, N
  • Tarride, Jean-Eric
  • Paes, B

publication date

  • December 2023